A phase II first-line study of gemcitabine, carboplatin, and Bevacizumab in advanced stage nonsquamous non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 11, 2010, Pages 1821-1825

  Clément Duchêne, Christelle ^a,b   Krupitskaya, Yelena ^a   Ganjoo, Kristen ^a,c   Lavori, Philip ^d   McMillan, Alex ^d   Kumar, Atul ^a   Zhao, Gary ^e   Padda, Sukhmani ^a   Zhou, Lisa ^f   Pedro Salcedo, Melanie San ^a   Colevas, A Dimitrios ^a   Wakelee, Heather A ^a  

^a Division of Oncology   (United States)

^b Division of Health Research and Policy   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Antiangiogenic agents; Lung cancer; Non small cell

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; BLEEDING; BLOOD PRESSURE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOXICITY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HEART FAILURE; HEART INFARCTION; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; LIVER DYSFUNCTION; LUNG ASPERGILLOSIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; WOUND DEHISCENCE;

EID: 78149471542     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f1d23c     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Rami-Porta R, Chansky K, Goldstraw P. Updated lung cancer staging system. Future Oncol 2009;5:1545-1553.
3. Group NM-AC. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-4625.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
5. Manegold C. Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2008;8:689-699.
6. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
8. Treat J, Edelman MJ, Belani CP, et al. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer. 2010 Mar 26. [Epub ahead of print].
9. Bajetta E, Stani SC, De Candis D, et al. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 2003;14:242-247.
10. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80.
11. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005;23:142-153.
12. Sederholm C. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol 2002;29:50-54.
13. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol. 2010 Feb 11. [Epub ahead of print].
14. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-3289.
15. Davila E, Lilenbaum R, Raez L, et al. Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC) (abstract no. 17009). J Clin Oncol 2006;24:667s.
16. Lilenbaum R, Raez L, Tseng J, et al. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:511-515.
17. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996;32A:243-248.
18. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380-8388.
19. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-3224.
20. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.